^Bouwer C, Stein DJ (1997). „Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression”.South African Medical Journal.87 (4 Suppl): 534—7, 540.PMID9180827.
^Appelberg BG, Syvälahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH (2001). „Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study”.The Journal of Clinical Psychiatry.62 (6): 448—52.PMID11465522.doi:10.4088/JCP.v62n0608.
^Yamada K, Yagi G, Kanba S (2003). „Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial”.Psychiatry and Clinical Neurosciences.57 (2): 183—7.PMID12667165.doi:10.1046/j.1440-1819.2003.01099.x.